Straight from the Desk
Syz the moment
Live feeds, charts, breaking stories, all day long.
- All
- us
- equities
- Food for Thoughts
- macro
- Bonds
- sp500
- Central banks
- Asia
- markets
- technical analysis
- investing
- bitcoin
- inflation
- interest-rates
- europe
- performance
- tech
- Commodities
- Crypto
- ETF
- AI
- geopolitics
- nvidia
- gold
- earnings
- Forex
- Real Estate
- oil
- bank
- nasdaq
- Volatility
- apple
- emerging-markets
- FederalReserve
- magnificent-7
- Alternatives
- energy
- switzerland
- sentiment
- trading
- Money Market
- tesla
- France
- ESG
- russia
- assetmanagement
- Middle East
- UK
- ethereum
- microsoft
- bankruptcy
- meta
- amazon
- Industrial-production
- Turkey
- Global Markets Outlook
- Healthcare
- recession
- africa
- china
- Market Outlook
- brics
- Focus
- shipping
- wages
Europe on its way to become retirement home
There are just three options to avoid a collapse: 1. Drastically increase retirement age 2. Cut pensions and healthcare 3. Skilled, educated immigration Source: Michel A.Arouet
Do you remember Moderna $MRNA ???
Moderna beats estimates but slashes guidance on low EU sales, competitive U.S. vaccine market. It is down -20% today and -79% from its covid all-time-high. Moderna: "Net product sales for Q2 24 were $184M, reflecting a 37% YoY decrease. This reduction aligns with the expected shift to a seasonal COVID-19 vaccine market.." Moderna had $241M in total sales in Q2 and $1.6B in total operating expenses. Adding interest income, they burned $1.27B in one quarter. Cash on balance sheet is down to $2.47B. I fully expect expect them to do large capital raise to dilute shareholders. Source: JaguarAnalytics, The Transcript
waouuu... this could be a major medical breakthrough...
Source: Mario Nawfal
New weight-loss drug ETF
“Roundhill Investments' GLP-1 & Weight Loss ETF (OZEM), which began trading last week, pairs leaders Eli Lilly and Novo Nordisk with players developing new treatments for weight loss and diabetes. CEO Dave Mazza said his firm is capitalizing on explosive growth potential in the industry…Eli Lilly and Novo Nordisk each hold a roughly 20% weighting in the ETF. The three next largest positions are Zealand Pharma, Amgen and Chugai Pharmaceutical, each of which have a weighting under 5%”. Source: CNBC, Bloomberg
(Bloomberg) - A surprising thing is happening to some women on weight-loss drugs who’ve struggled with fertility issues: They’re getting pregnant...
Source: Bloomberg, Carl Quintanilla
Investing with intelligence
Our latest research, commentary and market outlooks